The impact on utilities of differences in body weight among Canadian patients with type 2 diabetes

Lane, Susan; Levy, Adrian R.; Mukherjee, Jayanti; Sambrook, Jennifer; Tildesley, Hugh D.

doi:10.1185/03007995.2014.899207

Cited by 39 publications

(40 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For those unavailable in UKPDS 62 study, including end-stage renal disease (ESRD) and blindness [78], hypoglycaemia [79], per unit change in BMI [80], gastrointestinal adverse events [81] and urinary tract infection (UTI) [82], values were obtained from other published studies. Given the lack of utility data available for genital infections, it was assumed to be equivalent to that of UTI ( Table 7).…”

Section: Utilitiesmentioning

confidence: 99%

“…Furthermore, patients in the dapagliflozin arm experienced fewer symptomatic and severe hypoglycaemia events than that in the acarbose arm ( Table 8). a Utility decrements for most events were adopted from the UKPDS 62 study [77], except for end-stage renal disease and blindness [78], hypoglycaemia [79], BMI-related changes [80], gastrointestinal adverse events [81] and urinary tract infection [82]. Utility for genital infections was assumed to be equivalent to urinary tract infection.…”

Section: Predicted Health Eventsmentioning

confidence: 99%

See 1 more Smart Citation

Cost-Effectiveness of Dapagliflozin Versus Acarbose as A Monotherapy in Type 2 Diabetes in China

2016

Value in Health

View full text Add to dashboard Cite

ObjectiveTo estimate the long-term cost-effectiveness of dapagliflozin versus acarbose as monotherapy in treatment-naïve patients with type 2 diabetes mellitus (T2DM) in China. MethodsThe Cardiff Diabetes Model, an economic model designed to evaluate the cost-effectiveness of comparator therapies in diabetes was used to simulate disease progression and estimate the long-term effect of treatments on patients. Systematic literature reviews, hospital surveys, meta-analysis and indirect treatment comparison were conducted to obtain model-required patient profiles, clinical data and costs. Health insurance costs (2015¥) were estimated over 40 years from a healthcare payer perspective. Univariate and probabilistic sensitivity analyses were performed. ResultsThe model predicted that dapagliflozin had lower incidences of cardiovascular events, hypoglycemia and mortality events, was associated with a mean incremental benefit of 0.25 quality-adjusted life-years (QALYs) and with a lower cost of ¥8,439 compared with acarbose. This resulted in a cost saving of ¥33,786 per QALY gained with dapagliflozin. Sensitivity analyses determined that the results are robust. ConclusionDapagliflozin is dominant compared with acarbose as monotherapy for Chinese T2DM patients, with a little QALY gain and lower costs. Dapagliflozin offers a well-tolerated and cost-effective alternative medication for treatment-naive patients in China, and may have a direct impact in reducing the disease burden of T2DM.

show abstract

Section: Utilitiesmentioning

confidence: 99%

Section: Predicted Health Eventsmentioning

confidence: 99%

Cost-Effectiveness of Dapagliflozin Versus Acarbose as A Monotherapy in Type 2 Diabetes in China

2016

Value in Health

View full text Add to dashboard Cite

show abstract

“…Because there were no country-specific utility decrements for diabetes-related events in China, we mainly adopted data from the UKPDS 62 study [56], excluding end-stage renal disease (ESRD) and blindness [57], BMI-related changes [58], hypoglycemia episodes [59], and GI adverse events [60] which were obtained from other studies (Table 6). [57], BMIrelated changes [58], hypoglycemia [59], and GI adverse events [60] were obtained from other studies.…”

Section: Utilitiesmentioning

confidence: 99%

“…[57], BMIrelated changes [58], hypoglycemia [59], and GI adverse events [60] were obtained from other studies.…”

Section: Utilitiesmentioning

confidence: 99%

Cost-Effectiveness of Saxagliptin Versus Acarbose as Second-Line Therapy in Type 2 Diabetes in China

Shao

Zeng

et al. 2016

Value in Health

View full text Add to dashboard Cite

ObjectiveThis study assessed the long-term cost-effectiveness of saxagliptin+metformin (SAXA +MET) versus acarbose+metformin (ACAR+MET) in Chinese patients with type 2 diabetes mellitus (T2DM) inadequately controlled on MET alone. MethodsSystematic literature reviews were performed to identify studies directly comparing SAXA +MET versus ACAR+MET, and to obtain diabetes-related events costs which were modified by hospital surveys. A Cardiff Diabetes Model was used to estimate the long-term economic and health treatment consequences in patients with T2DM. Costs (2014 Chinese yuan) were calculated from the payer's perspective and estimated over a patient's lifetime. ResultsSAXA+MET predicted lower incidences of most cardiovascular events, hypoglycemia events and fatal events, and decreased total costs compared with ACAR+MET. For an individual patient, the quality-adjusted life-years (QALYs) gained with SAXA+MET was 0.48 more than ACAR+MET at a cost saving of ¥18,736, which resulted in a cost saving of ¥38,640 per QALY gained for SAXA+MET versus ACAR+MET. Results were robust across various univariate and probabilistic sensitivity analyses. ConclusionSAXA+MET is a cost-effective treatment alternative compared with ACAR+MET for patients with T2DM in China, with a little QALYs gain and lower costs. SAXA is an effective, well-tolerated drug with a low incidence of adverse events and ease of administration; it is anticipated to be an effective second-line therapy for T2DM treatment.

show abstract

“…'The impact on utilities of differences in body weight among Canadian patients with type 2 diabetes' by Lane et al published in this issue aims to investigate the effect of weight in type 2 diabetic individuals as a quality of life determinant by measuring the utilities 13 . The study itself is inspired by similar work done by another investigator, in the UK (Matza et al 14 ).…”

mentioning

confidence: 99%

Weight adds weight to declining quality of life in diabetes

Aravind

Deshpande²

2014

Current Medical Research and Opinion

View full text Add to dashboard Cite

The impact on utilities of differences in body weight among Canadian patients with type 2 diabetes

Abstract: The preferences of Canadian patients with type 2 DM for diabetes-related health states varied according to the weight, and quality of life impact, associated with that health state. Increased weight had a greater effect on utilities than decreased weight.

Cited by 39 publications

References 21 publications

Cost-Effectiveness of Dapagliflozin Versus Acarbose as A Monotherapy in Type 2 Diabetes in China

Cost-Effectiveness of Dapagliflozin Versus Acarbose as A Monotherapy in Type 2 Diabetes in China

Cost-Effectiveness of Saxagliptin Versus Acarbose as Second-Line Therapy in Type 2 Diabetes in China

Weight adds weight to declining quality of life in diabetes

Contact Info

Product

Resources

About